Redx Pharma Plc (LON:REDX) has announced that its abstract has been accepted for presentation as a poster at the American Association for Cancer Research Annual meeting in Chicago in April.
The AIM-listed drug development company said the poster relates to its lead candidate, RXC004, a potent and selective, orally bioavailable porcupine inhibitor, which is currently being investigated in a phase 1/2a clinical trial in patients with hard to treat cancers.
READ: Redx Pharma starts dosing on its RXC004 cancer study
It is expected that initial data from the 1a segment of this trial will be available in the second half of 2018.
Richard Armer, Redx Pharma's chief scientific officer said: “We are delighted that our abstract has been accepted at such a high profile conference.”
He added: “We are excited by the potential of RXC004 as a treatment for challenging cancers and look forward to announcing the first data from our clinical development programme with this compound.”